The Real-World Efficacy of Fixed Triple Inhalation Therapy in the Treatment of Moderate COPD Patients (RATIONALE Study)
András Südi,Balázs Sánta,Alpár Horváth,Gábor Tomisa,Zsolt Abonyi-Tóth,György Rokszin,Noémi Eszes,Veronika Müller,Lilla Tamási
DOI: https://doi.org/10.2147/copd.s474354
2024-08-30
International Journal of COPD
Abstract:András Südi, 1 Balázs Sánta, 2, 3 Alpár Horváth, 1, 2 Gábor Tomisa, 1 Zsolt Abonyi-Tóth, 4, 5 György Rokszin, 4 Noémi Eszes, 1 Veronika Müller, 1 Lilla Tamási 1 1 Department of Pulmonology, Semmelweis University, Budapest, Hungary; 2 Medical Department, Chiesi Hungary Kft, Budapest, Hungary; 3 Department of Pulmonology, Szent Borbála County Hospital, Tatabanya, Hungary; 4 Rx Target Kft, Budapest, Hungary; 5 Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary Correspondence: Lilla Tamási, Department of Pulmonology, Semmelweis University, Töm&odblac Str. 25-29, Budapest, 1083, Hungary, Fax +36-1- 214-2498, Email Purpose: COPD affects more than 300 million people worldwide, requiring inhalation treatment. Novel triple formulations of ICS, LABAs and LAMAs are becoming the mainstay of treatment, however there is still a lack of clinical evidence for personalized therapy. Patients and Methods: RATIONALE was a non-interventional, prospective, 52 week study, assessing the effectiveness of beclometasone/formoterol/glycopyrronium-bromide (BDP/FF/G), in symptomatic COPD patients, with moderate airflow obstruction. The study included 4 visits, where data on demographic parameters, exacerbations, symptoms, quality of life (based on the EQ-5D-3L questionnaire) and lung function were collected. Data on adherence to treatment, based on prescriptions filled was collected from the database of the National Health Insurance Fund, with the patients' consent. The primary objective was the change of adherence to treatment during the study, compared to baseline. Results: Altogether 613 patients had been enrolled. Their average age was 64.56 years and 50.5% were female. The average CAT score was 20.86, and most patients had suffered minimum one exacerbation (82.2%). Average FEV1 was 59.6%. Most patients had some limitation in one or more dimensions of EQ-5D-3L, with an average visual analogue scale score (VAS) of 60.31. After 12 months of treatment, adherence improved significantly – proportion of patients in the highest adherence group increased from 29.8% to 69.7% (p< 0.001). The average CAT score improved by 7.02 points (95% CI 5.82– 8.21, p< 0.001). There was a significant improvement in all dimensions of EQ-5D-3L, with an average increase of 17.91 (95% CI 16.51– 19.31, p< 0.001) points in the VAS score. Exacerbation frequency also decreased significantly. Conclusion: Although limitations of observational studies are present, we observed that early introduction of fixed triple combination results in a marked improvement in adherence to treatment, symptom scores, exacerbation frequency and quality of life. The optimal choice of treatment is crucial for reaching the highest possible adherence. Keywords: COPD, fixed triple combination, inhalation treatment, quality of life Chronic obstructive pulmonary disease (COPD) is the second most common respiratory disease and currently the third leading cause of death. 1 It affects over 300 million people worldwide, with 185,000 diagnosed patients in Hungary. 2 Its primary symptoms include exertional dyspnea, cough, and sputum production, significantly impacting patients' quality of life and daily activities. The disease progresses over time, leading to worsening respiratory function and exacerbation of symptoms despite appropriate treatment. Periodic acute exacerbations, triggered by viral or bacterial infections, air pollution, or other environmental factors, also characterize COPD. The goal of maintenance therapy for COPD is to reduce the risk of exacerbations, prevent their occurrence, alleviate daily symptoms, improve quality of life, and preserve respiratory function. 3 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides guidelines for the diagnosis and management of COPD. The choice of maintenance therapy depends on exacerbation frequency and symptoms, particularly dyspnea. 4 Options include long-acting muscarinic antagonists (LAMA), beta-adrenergic agonists (LABA), dual bronchodilator therapy (LABA/LAMA), and combination therapy with inhaled corticosteroids (ICS/LABA). The latest treatment option includes fixed triple combination therapies containing three different active ingredients (ICS/LABA/LAMA), recommended when patients present with exacerbation and elevated blood eosinophil counts or when exacerbations occur despite established dual bronchodilator therapy. 4 The initiation of therapy with fixed triple combinations was newly introduced in the 2023 GOLD guidelines due to recognition of their high efficacy. Bas -Abstract Truncated-
respiratory system